nGageIT Digital Health™
Sensors that can detect the medication you take from your breath
Intelligent Breath Sensor Technology
capable of significantly improving disease and diagnostic screening and testing, precision medicine, and medication adherence programs
nGageIT Digital Health™ is a breath diagnostics company pioneering new medical treatment breakthroughs. This starts with medication adherence, treatment verification and compliance, and progresses to patient wellness factors and biopatterns, precision medicine, and more advanced diagnostic applications.
AT THE POINT OF CARE
nGageIT Digital Health™ nanoparticle biosensors are revolutionary mobile point-of-care devices that are the size of a smart phone.
DIRECT BREATH TESTING
Our direct breath testing means there is no requirement for handling of pre-concentration or pre-processing of the exhaled breath samples.
REAL-TIME CLOUD PROCESSING
No processing or transportation time means results are processed against existing VOC libraries in the cloud, and delivered in near-real-time.
CLINICAL RESULTS IN MINUTES
Secure cloud-based digital lab processing power outputs test results to care providers and teams in minutes rather than days or weeks.
Intelligent nanosensors that are designed exclusively to map the human exhaled breath
Our sensors can enable the delivery of critical real-time adherence, wellness, and behavioral data, enabling the development of effective and efficient risk monitoring and management systems, interventions, improved adherence, and improved patient health and outcomes.
Learn how we can address specific market challenges
We deliver significant Ai-driven insights into patient behaviors and treatment results.
Learn more about how our Insights can drive patient outcomes
Medication non-adherence is an up-to USD $500 billion dollar problem in the United States annually
Chronic Conditions 50%
Medication Adherence 53%
Treatment Compliance 32%
More than 80% of lung cancer patients will survive for at least a year if diagnosed at the earliest stage compared to around 15% for people diagnosed with the most advanced stage of disease.
Survival rates comparing stage 1 and stage 4 lung cancer
The global clinical trials market is said to be expected to reach USD 65.2 billion by 2025.
The globalization of clinical trials (led by the emergence of CROs as a driving force in the clinical trials market), development of new treatments and evolving technologies such as personalized medicine and programs as well as digital monitoring services along with the increasing demand for data and analytics by way of CRO support all are said to play key roles in shaping the future of clinical trials.
However, the complexity of trials, patient recruitment, adoption of technology, regulatory requirements, high cost levels and many others issues
create challenges conducting and working in the clinical trials market. High rates of failure resulting from lengthy and complex study designs and the constraints driven by the complexities of guidelines have resulted in all-time high clinical trials. Additionally, patient access to appropriate clinical trials and engagement is declining, and staff and operations management is more challenging than ever.
The overall cost of failed clinical trails is extremely high, with estimates varying between $800 million and $1.4 billion USD.